Xin Lang Zheng Quan·2025-11-13 12:09Core Viewpoint - The discussion at the Shanghai Securities Exchange International Investors Conference highlighted the potential for world-class pharmaceutical companies to emerge from China, driven by innovation, supportive policies, and collaborative teams [1][3]. Group 1: Industry Opportunities - High Fei, Chairman and General Manager of Hangzhou Aotai Biotechnology Co., believes that world-class enterprises will definitely emerge in China, emphasizing the importance of industry opportunities, international environment, and continuous innovation [3]. - Xiao Zhihua, Chairman of Shanghai Aopumai Biotechnology Co., pointed out that while challenges exist for Chinese companies to become truly global in a time of globalization retreat, he remains confident that world-class enterprises will emerge [3]. Group 2: Importance of Policy and Market - Zhang Lianshan, Global R&D President of Jiangsu Hengrui Medicine Co., stressed the significance of confidence and policy support, stating that biopharmaceutical companies must first establish value in the Chinese market to generate global value [3]. - The discussion concluded that with improved innovation capabilities and ongoing policy enhancements, the Chinese pharmaceutical industry is likely to nurture world-class enterprises in the future [3].